Every abortion facilitated cancels the state's ban
A unanimous federal appeals court ruling in New Orleans has placed the mailing of mifepristone — the most commonly used abortion medication in the United States — beyond legal reach, requiring instead that patients obtain the drug only through in-person clinic visits. The decision, authored by judges appointed by Republican presidents, overrides more than two decades of FDA safety determinations in a move that courts have historically declined to make. For the millions of women who have come to rely on telehealth prescriptions, particularly those in rural communities and states with abortion bans, the ruling closes a door that many had no other way through. The case now moves toward the Supreme Court, where the question of who holds authority over drug safety — judges or scientists — may finally be forced into the open.
- A federal appeals court has stripped the FDA of its authority over mifepristone distribution, a rare judicial override that sends shockwaves through both reproductive healthcare and the broader principle of scientific agency deference.
- Roughly one in four abortions in the U.S. depends on telehealth prescriptions — a channel the ruling eliminates nationwide, not just in states where abortion is already banned.
- Rural patients, low-income women, people with disabilities, and survivors of domestic violence face the sharpest immediate harm, as in-person clinic visits become the only legal path to medication abortion.
- Manufacturers and civil liberties groups are racing to the Supreme Court for emergency relief, while the conservative-majority bench has already once preserved mifepristone access — though on narrow procedural grounds that left the deeper fight unresolved.
- The ruling lands as the Trump administration conducts its own review of mifepristone's safety, creating an uneasy standoff between judicial action and executive process, with no clear timeline for resolution.
On a Friday in May, a three-judge panel of the 5th U.S. Circuit Court of Appeals issued a unanimous ruling that will fundamentally alter how medication abortion reaches patients across the country. The court blocked the mailing of mifepristone prescriptions nationwide, requiring the drug to be dispensed only in person at clinics — overturning FDA regulations in a move that federal courts have historically avoided, preferring to defer to the agency's scientific expertise.
Mifepristone, approved in 2000 and typically used alongside misoprostol to end early pregnancies, now accounts for the majority of abortions in the United States. Telehealth prescriptions alone represent roughly one in four of those procedures. Judge Kyle Duncan, a Trump appointee, sided with Louisiana's argument that mailing the drug undermines the state's total ban on abortion, writing that every abortion facilitated by the FDA's action effectively cancels Louisiana's law.
The ruling sets aside more than two decades of FDA monitoring and dozens of studies involving thousands of women. Under President Biden, the agency had relaxed strict prescribing requirements during the COVID-19 pandemic, concluding that patients could safely use the medication without direct supervision. The three judges — all appointed by Republican presidents — overruled that scientific judgment, noting that the FDA under Trump is conducting a new safety review with no announced completion date.
The human cost is immediate and uneven. The ACLU warned that rural communities, low-income patients, people with disabilities, domestic violence survivors, and communities of color — those already facing the steepest barriers — will bear the greatest burden. GenBioPro, which manufactures generic mifepristone, condemned the decision as an attempt to erase decades of established safety data.
Opponents of abortion access celebrated the ruling as a significant victory, while manufacturers signaled plans to seek emergency relief from the Supreme Court. The high court unanimously preserved mifepristone access in 2024, but sidestepped the core legal questions by ruling that the plaintiffs lacked standing to sue. Whether the justices will now confront those questions directly remains uncertain — but for millions of women, particularly those without the means to travel, the barriers are already real.
On Friday, a three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans issued a unanimous decision that will reshape how one of America's most commonly used abortion methods reaches patients. The court blocked the mailing of mifepristone prescriptions nationwide, requiring instead that the drug be dispensed only in person at clinics. The ruling overturns regulations set by the Food and Drug Administration—a rare move that judges have historically avoided, deferring instead to the agency's scientific expertise on drug safety.
Mifepristone, approved in 2000, is typically used alongside a second medication called misoprostol to end early pregnancies. Surveys show that the majority of abortions in the U.S. are now provided via pills, and roughly one in four are prescribed through telehealth. The drug's rise in prominence has made it a target for abortion opponents, who have pursued both legislative and legal strategies to restrict it. Judge Kyle Duncan, appointed by President Donald Trump, sided with Louisiana's argument that allowing the drug to be mailed undermines the state's ban on abortion at all stages of pregnancy. The ruling stated that every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortions.
The decision represents a significant departure from how federal courts typically handle FDA determinations. For more than two decades, the agency monitored mifepristone's use and reviewed dozens of studies involving thousands of women. Based on that evidence, FDA officials under President Joe Biden dropped strict prescribing requirements during the COVID-19 pandemic, concluding that women could safely use the pill without direct medical supervision. The initial restrictions had been imposed because of rare cases of excessive bleeding. Now, the three judges—all appointed by Republican presidents—have overruled that scientific judgment. They noted that the FDA, under Trump's direction, is conducting a new review of mifepristone's safety but could not say when it might be complete.
The immediate impact extends far beyond states with abortion bans. Telehealth prescriptions have become common even in states where abortion remains legal, and the ruling blocks them everywhere. Julia Kaye, a lawyer with the ACLU, warned that the decision will harm rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence, and communities of color—populations already facing the greatest barriers to abortion access. GenBioPro, which manufactures generic mifepristone, called the decision an attempt to ignore decades of safe use and the FDA's rigorous science.
Opponents of abortion framed the ruling differently. Carol Tobias, president of the National Right to Life Committee, said women deserve better than an abortion-by-mail system that prioritizes ideology over safety. Louisiana's Republican attorney general, Liz Murrill, said she looked forward to continuing to defend what she called women and babies as the case proceeds. Anti-abortion groups celebrated the decision as a major victory, with one activist criticizing even the Trump administration for moving too slowly in its own review of the drug.
The ruling is in effect while the case works through the courts, and manufacturers have already signaled their intention to seek emergency relief from the U.S. Supreme Court. The conservative-majority Supreme Court overturned abortion as a nationwide right in 2022 but unanimously preserved access to mifepristone two years later—though that decision sidestepped the core issues by ruling that the doctors behind the case lacked legal standing to sue. Whether the high court will revisit mifepristone access now remains an open question, but the stakes are clear: millions of women across the country, particularly those in rural areas and those without resources to travel, face immediate barriers to medication abortion and miscarriage care.
Notable Quotes
This is going to affect patients' access to abortion and miscarriage care in every state in the nation. When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.— Julia Kaye, ACLU lawyer
Women deserve better than an abortion-by-mail system that prioritizes ideology over safety.— Carol Tobias, National Right to Life Committee president
The Hearth Conversation Another angle on the story
Why would a court override the FDA on drug safety? That seems unusual.
It is. Judges have historically deferred to the agency's scientific judgment. But this panel of Republican-appointed judges sided with Louisiana's argument that the FDA's rules were effectively nullifying the state's abortion ban. They treated it as a legal question about state sovereignty rather than a scientific one about drug safety.
But the FDA spent twenty years studying this drug. What changed?
The science didn't change. What changed is the political environment. The Trump administration directed the FDA to conduct a new review, and the court essentially used that ongoing review as justification to overturn the existing regulations—even though the FDA said it doesn't know when the new review will be finished.
Who gets hurt most by this?
The people who already face the biggest obstacles: rural women, low-income women, women with disabilities, women in abusive relationships. They relied on being able to receive the pill by mail. Now they either have to travel to a clinic or travel to another state entirely.
Does this affect states where abortion is still legal?
Yes, that's what makes it so sweeping. Even in states where abortion is allowed, telehealth prescriptions are now blocked. The ruling doesn't distinguish between states with bans and states without them.
What happens next?
The manufacturers are asking the Supreme Court for emergency relief. The high court has already ruled on mifepristone once, in 2024, but that decision was narrow—it didn't address the core safety questions. This case might force them to engage with those questions directly.